IOSP Stock Analysis: Innospec | NASDAQ

Fuel Additives, Personal Care, Oilfield Services, Mining Reagents

Total Rating 69

Safety 83

Buy Signal 0.87

Specialty Chemicals
Industry Rotation: +2.7

Market Cap: 2.40B
Avg Turnover: 20.1M

Risk 3d forecast

Volatility24.2%

VaR 5^th Pctl3.98%

VaR vs Median-0.18%

Reward TTM

Sharpe Ratio0.99

Rel. Str. IBD84.5

Rel. Str. Peer Group86.9

Character TTM

Beta0.695

Beta Downside0.743

Hurst Exponent0.541

Drawdowns 3y

Max DD48.42%

CAGR/Max DD0.01

CAGR/Mean DD0.03

EPS (Earnings per Share)

EPS CAGR: -8.10%
EPS Trend: -75.7%

Last SUE: 2.62
Qual. Beats: 1

Revenue

Rev. CAGR: -3.48%
Rev. Trend: -85.5%

Last SUE: 1.50
Qual. Beats: 2

Warnings

No concerns identified

Tailwinds

Rs Leader

Idiosyncratic Leader

Confidence

Seasonality 11.7 years of data

Jan +0.8% 19

Feb -3.0% 18

Mar -1.9% 33

Apr +0.2% 7

May +3.1% 37

Jun -2.1% 27

Jul +2.0% 23

Aug -1.9% 5

Sep -3.6% 31

Oct -0.4% 0

Nov +9.5% 73

Dec +1.8% 14

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: IOSP Innospec

Innospec Inc. (IOSP) is a U.S.-based specialty chemicals manufacturer headquartered in Englewood, Colorado, founded in 1938 and formerly known as Octel Corp. until its 2006 renaming. The company operates globally across the Americas, Europe, the Middle East, Africa, and Asia-Pacific through three reporting segments: Performance Chemicals, Fuel Specialties, and Oilfield Services.

Its product portfolio centers on chemical additives and formulated solutions rather than bulk commodity chemicals. The Fuel Specialties segment supplies additives for diesel, jet, marine, fuel oil, and other fuels used in commercial trucking, aviation, marine engines, power generation, and industrial machinery, with demand largely driven by emissions and fuel-quality regulations such as ultra-low-sulfur diesel standards and IMO marine fuel rules.

The Performance Chemicals segment delivers technology-based solutions into personal care, home care, agrochemical, construction, and mining markets, while Oilfield Services provides chemistries for drilling, completion, production, and drag-reducing applications in oil and gas. Innospecs customer base spans large multinational industrial firms, fuel marketers and retailers, oilfield service companies, and exploration and production operators.

Headlines to Watch Out For

IMO sulfur regulations boost Fuel Specialties additive demand
Oilfield Services revenue swings with crude prices and rig counts
Performance Chemicals margins hinge on raw material costs

Piotroski VR-10 (Strict) 4.5

Net Income: 121.5m TTM > 0 and > 6% of Revenue
FCF/TA: 0.04 > 0.02 and ΔFCF/TA -1.30 > 1.0
NWC/Revenue: 35.64% < 20% (prev 35.31%; Δ 0.33% < -1%)
CFO/TA 0.07 > 3% & CFO 125.5m > Net Income 121.5m
Net Debt (-202.3m) to EBITDA (171.5m): -1.18 < 3
Current Ratio: 2.78 > 1.5 & < 3
Outstanding Shares: last quarter (24.7m) vs 12m ago -1.34% < -2%
Gross Margin: 27.46% > 18% (prev 28.40%; Δ -0.94% > 0.5%)
Asset Turnover: 100.9% > 50% (prev 99.15%; Δ 1.73% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM)

Altman Z'' 7.70

A: 0.36 (Total Current Assets 1.02b - Total Current Liabilities 368.1m) / Total Assets 1.85b
B: 0.62 (Retained Earnings 1.14b / Total Assets 1.85b)
C: 0.08 (EBIT TTM 139.5m / Avg Total Assets 1.83b)
D: 2.71 (Book Value of Equity 1.34b / Total Liabilities 495.2m)
Altman-Z'' = 7.70 = AAA

Beneish M -2.85

DSRI: 1.18 (Receivables 408.6m/336.1m, Revenue 1.84b/1.79b)
GMI: 1.03 (GM 28.40% / 27.46%)
AQI: 0.96 (AQ_t 0.26 / AQ_t-1 0.27)
SGI: 1.03 (Revenue 1.84b / 1.79b)
TATA: -0.00 (NI 121.5m - CFO 125.5m) / TA 1.85b)
Beneish M = -2.85 (Cap -4..+1) = A

What is the price of IOSP shares?

As of October 07, 2026, the stock is trading at USD 98.55 with a total of 233,648 shares traded. Over the past week, the price has changed by +1.89%, over one month by +5.55%, over three months by +19.58% and over the past year by +28.06%.

Current recommended Stop Loss: 93.40 (which is 5.2% or 2.3 ATR below the current price).

Is IOSP a buy, sell or hold?

Innospec has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy IOSP.

StrongBuy: 2
Buy: 1
Hold: 0
Sell: 0
StrongSell: 0

What are the forecasts/targets for the IOSP price?

Analysts Target Price	101	2.5%

Innospec (IOSP) - Fundamental Data Overview as of 05 October 2026

Market Cap USD = 2.40b (2.40b USD * 1.0 USD.USD)
P/E Trailing = 19.8796
P/E Forward = 15.0376
P/S = 1.3025
P/B = 1.7633
P/EG = 0.6612
Revenue TTM = 1.84b USD
EBIT TTM = 139.5m USD
EBITDA TTM = 171.5m USD
Long Term Debt = 33.6m USD (estimated: total debt 47.9m - short term 14.3m)
Short Term Debt = 14.3m USD (from shortTermDebt, last quarter)
Debt = 47.9m USD (from shortLongTermDebtTotal, last quarter) (leases 47.9m already included)
Net Debt = -202.3m USD (calculated: Debt 47.9m - CCE 250.2m)
Enterprise Value = 2.20b USD (2.40b + Debt 47.9m - CCE 250.2m)
Interest Coverage Ratio = unknown (Ebit TTM 139.5m / Interest Expense TTM 0.0)
EV/FCF = 33.85x (Enterprise Value 2.20b / FCF TTM 64.9m)
FCF Yield = 2.95% (FCF TTM 64.9m / Enterprise Value 2.20b)
FCF Margin = 3.52% (FCF TTM 64.9m / Revenue TTM 1.84b)
Net Margin = 6.60% (Net Income TTM 121.5m / Revenue TTM 1.84b)
Gross Margin = 27.46% ((Revenue TTM 1.84b - Cost of Revenue TTM 1.34b) / Revenue TTM)
Gross Margin QoQ = 28.14% (prev 27.25%)
Tobins Q-Ratio = 1.19 (Enterprise Value 2.20b / Total Assets 1.85b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 47.9m)
Taxrate = 14.65% (21.0m / 143.3m)
NOPAT = 119.1m (EBIT 139.5m * (1 - 14.65%))
Current Ratio = 2.78 (Total Current Assets 1.02b / Total Current Liabilities 368.1m)
Debt / Equity = 0.04 (Debt 47.9m / totalStockholderEquity, last quarter 1.34b)
Debt / EBITDA = -1.18 (Net Debt -202.3m / EBITDA 171.5m)
Debt / FCF = -3.12 (Net Debt -202.3m / FCF TTM 64.9m)
Total Stockholder Equity = 1.33b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.65% (Net Income 121.5m / Total Assets 1.85b)
RoE = 9.15% (Net Income TTM 121.5m / Total Stockholder Equity 1.33b)
RoCE = 10.25% (EBIT 139.5m / Capital Employed (Equity 1.33b + L.T.Debt 33.6m))
RoIC = 8.50% (NOPAT 119.1m / Invested Capital 1.40b)
WACC = 8.26% (E(2.40b)/V(2.45b) * Re(8.43%) + D(47.9m)/V(2.45b) * Rd(0.0%) * (1-Tc(0.15)))
Discount Rate = 8.43% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -88.14 | Cagr: -0.64%
[DCF] Terminal Value 73.10% ; FCFF base≈73.7m ; Y1≈64.6m ; Y5≈52.2m
[DCF] Fair Price = 42.24 (EV 838.2m - Net Debt -202.3m = Equity 1.04b / Shares 24.6m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -75.69 | EPS CAGR: -8.10% | SUE: 2.62 | # QB: 1
Revenue Correlation: -85.52 | Revenue CAGR: -3.48% | SUE: 1.50 | # QB: 2
EPS current Quarter (2026-09-30): EPS=1.27 | Chg30d=+2.42% | Revisions=+40% | Analysts=3
EPS current Year (2026-12-31): EPS=4.94 | Chg30d=+3.28% | Revisions=+40% | GrowthEPS=-6.3% | GrowthRev=+7.1%
EPS next Year (2027-12-31): EPS=6.15 | Chg30d=+1.26% | Revisions=+25% | GrowthEPS=+24.6% | GrowthRev=+5.9%
[Analyst] Revisions Ratio: +62% (up=5, down=0)